We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Thermo Fisher Scientific (TMO - Free Report) closed at $528.31, marking a +0.45% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.37%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq lost 1.26%.
Coming into today, shares of the maker of scientific instrument and laboratory supplies had gained 2.98% in the past month. In that same time, the Medical sector gained 0.08%, while the S&P 500 gained 4.31%.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $5.43 per share, which would represent a year-over-year decline of 1.45%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.99 billion, up 0.2% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $23.69 per share and revenue of $45.3 billion, which would represent changes of +1.94% and +0.86%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Thermo Fisher Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Thermo Fisher Scientific is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 22.2. Its industry sports an average Forward P/E of 29.06, so we one might conclude that Thermo Fisher Scientific is trading at a discount comparatively.
Also, we should mention that TMO has a PEG ratio of 2.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TMO's industry had an average PEG ratio of 2.61 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 117, which puts it in the top 47% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Thermo Fisher Scientific (TMO - Free Report) closed at $528.31, marking a +0.45% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.37%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq lost 1.26%.
Coming into today, shares of the maker of scientific instrument and laboratory supplies had gained 2.98% in the past month. In that same time, the Medical sector gained 0.08%, while the S&P 500 gained 4.31%.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $5.43 per share, which would represent a year-over-year decline of 1.45%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.99 billion, up 0.2% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $23.69 per share and revenue of $45.3 billion, which would represent changes of +1.94% and +0.86%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Thermo Fisher Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Thermo Fisher Scientific is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 22.2. Its industry sports an average Forward P/E of 29.06, so we one might conclude that Thermo Fisher Scientific is trading at a discount comparatively.
Also, we should mention that TMO has a PEG ratio of 2.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TMO's industry had an average PEG ratio of 2.61 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 117, which puts it in the top 47% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.